265 related articles for article (PubMed ID: 15623593)
1. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
[TBL] [Abstract][Full Text] [Related]
2. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers.
Stathopoulou A; Mavroudis D; Perraki M; Apostolaki S; Vlachonikolis I; Lianidou E; Georgoulias V
Anticancer Res; 2003; 23(2C):1883-90. PubMed ID: 12820473
[TBL] [Abstract][Full Text] [Related]
3. Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system.
Stathopoulou A; Gizi A; Perraki M; Apostolaki S; Malamos N; Mavroudis D; Georgoulias V; Lianidou ES
Clin Cancer Res; 2003 Nov; 9(14):5145-51. PubMed ID: 14613993
[TBL] [Abstract][Full Text] [Related]
4. Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.
Ignatiadis M; Perraki M; Apostolaki S; Politaki E; Xenidis N; Kafousi M; Stathopoulos E; Lianidou E; Sotiriou C; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2007 Dec; 7(11):883-9. PubMed ID: 18269779
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of disseminated tumor cells as detected by quantitative real-time reverse-transcriptase polymerase chain reaction in patients with breast cancer.
Benoy IH; Elst H; Philips M; Wuyts H; Van Dam P; Scharpé S; Van Marck E; Vermeulen PB; Dirix LY
Clin Breast Cancer; 2006 Jun; 7(2):146-52. PubMed ID: 16800974
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.
Xenidis N; Ignatiadis M; Apostolaki S; Perraki M; Kalbakis K; Agelaki S; Stathopoulos EN; Chlouverakis G; Lianidou E; Kakolyris S; Georgoulias V; Mavroudis D
J Clin Oncol; 2009 May; 27(13):2177-84. PubMed ID: 19332733
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.
Rack B; Jückstock J; Günthner-Biller M; Andergassen U; Neugebauer J; Hepp P; Schoberth A; Mayr D; Zwingers T; Schindlbeck C; Friese K; Janni W
Arch Gynecol Obstet; 2012 Feb; 285(2):485-92. PubMed ID: 21717141
[TBL] [Abstract][Full Text] [Related]
8. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
[TBL] [Abstract][Full Text] [Related]
9. Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients.
Masuda TA; Kataoka A; Ohno S; Murakami S; Mimori K; Utsunomiya T; Inoue H; Tsutsui S; Kinoshita J; Masuda N; Moriyama N; Mori M
Int J Oncol; 2005 Mar; 26(3):721-30. PubMed ID: 15703829
[TBL] [Abstract][Full Text] [Related]
10. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance.
Stathopoulou A; Vlachonikolis I; Mavroudis D; Perraki M; Kouroussis Ch; Apostolaki S; Malamos N; Kakolyris S; Kotsakis A; Xenidis N; Reppa D; Georgoulias V
J Clin Oncol; 2002 Aug; 20(16):3404-12. PubMed ID: 12177100
[TBL] [Abstract][Full Text] [Related]
11. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
J Urol; 2004 Apr; 171(4):1461-6. PubMed ID: 15017198
[TBL] [Abstract][Full Text] [Related]
12. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection.
Pinzani P; Salvadori B; Simi L; Bianchi S; Distante V; Cataliotti L; Pazzagli M; Orlando C
Hum Pathol; 2006 Jun; 37(6):711-8. PubMed ID: 16733212
[TBL] [Abstract][Full Text] [Related]
13. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse.
Giatromanolaki A; Koukourakis MI; Kakolyris S; Mavroudis D; Kouroussis C; Mavroudi C; Perraki M; Sivridis E; Georgoulias V
Int J Cancer; 2004 Feb; 108(4):620-7. PubMed ID: 14696130
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.
Georgoulias V; Bozionelou V; Agelaki S; Perraki M; Apostolaki S; Kallergi G; Kalbakis K; Xyrafas A; Mavroudis D
Ann Oncol; 2012 Jul; 23(7):1744-50. PubMed ID: 22377561
[TBL] [Abstract][Full Text] [Related]
15. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy.
Kasimir-Bauer S; Mayer S; Bojko P; Borquez D; Neumann R; Seeber S
Clin Cancer Res; 2001 Jun; 7(6):1582-9. PubMed ID: 11410494
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.
Xenidis N; Vlachonikolis I; Mavroudis D; Perraki M; Stathopoulou A; Malamos N; Kouroussis C; Kakolyris S; Apostolaki S; Vardakis N; Lianidou E; Georgoulias V
Ann Oncol; 2003 Jun; 14(6):849-55. PubMed ID: 12796021
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.
Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J
Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
19. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
[TBL] [Abstract][Full Text] [Related]
20. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
